The LASERBLOOD Horizon Europe project will expand its consortium by integrating COMPLEAR, significantly boosting the project's implementation and impact. COMPLEAR's inclusion will establish a comprehensive regulatory framework for the development of the laser-based In Vitro Diagnostic (IVD) technology for the early diagnosis of pancreatic cancer, the project's primary goal. With COMPLEAR expertise, LASERBLOOD will develop the technology in accordance with the European Union (EU) In Vitro Diagnostic Regulation (IVDR - Regulation EU 2017/746) and United States (US) Food and Drug Administration (FDA) requirements, streamlining future approvals and market adoption. This alignment with global standards will enhance the credibility, safety, and market readiness of LASERBLOOD’s technology. COMPLEAR's expertise will boost the development of the IVD prototype, enriching the consortium’s knowledge in IVD regulations and promoting effective transnational collaboration. In turn, COMPLEAR will gain valuable experience in scientific research and management of important projects, enhancing its role in the European research community. Its participation will support excellence in Widening countries and its integration into the LASERBLOOD consortium will expand the project’s outreach by fostering new networks in the diagnostics sectors and cross-border knowledge exchange. In addition, COMPLEAR will provide access to new talent pools and stakeholders. This collaboration will improve the overall quality and reach of the project.